ESMO 2020
Let's collaborate Boehringer Ingelheim

ESMO 2020

European Society for Medical Oncology 2020

At the 2020 ESMO virtual meeting, Boehringer Ingelheim presented the latest data on their cancer research program across multiple tumor types.

 

Please see below for more information and downloadable versions of our ESMO publications.

 

Virtual exhibit

 

Click here to view our latest virtual exhibit.

 

1 virtual exhibit
3 publications
September 19 – Monday, September 21, 2020
Virtual format
Publications

Browse through the publications below to learn more about our emerging data.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumor Type
  • All tumor types
Saturday, September 19 – Monday, September 21, 2020
Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: initial results in patients with solid tumors
Author(s): Girard et al.
Oral Presentation
Tumor Type(s): solid tumors
Presentation Number: 533MO
Afatinib* in Asian and non-Asian patients with EGFR mutation-positive NSCLC harboring uncommon mutations
Author(s): Yang et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer (NSCLC)
Presentation Number: 1341P
Efficacy and safety of nintedanib**+ docetaxel in lung adenocarcinoma patients after failure of previous immune checkpoint inhibitor therapy: updated results from the ongoing non-interventional study VARGADO (NCT02392455)
Author(s): Grohé et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer (NSCLC)
Presentation Number: 1372P
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

RELATED INFORMATION

About Afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib.

About Nintedanib

A detailed look at nintedanib’s mechanism of action and the role of angiogenesis in cancer.

Our Pipeline

Find out more about our clinical development pipeline

Pipeline compounds shown here are under preclinical and/or clinical investigation, and have not been approved. Their safety and efficacy have not been established.

 

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here . Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

 

© 2020 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: September 2020

Back to top